NEW YORK, May 13, 2014 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that Merril Hoge, former star NFL player and an on-air analyst for ESPN, has joined its Board of Advisors.
According to Merril Hoge, "After tearing a ligament in my elbow I tried to rehab it to avoid surgery. During rehab I came across Dr. Victor and started to learn more about Cell Therapy. After extensive research, I chose cell therapy on my elbow, and thank goodness I did. I avoided surgery and a year of rehab and now have a healthy, healed elbow. I am excited to join IntelliCell's Board of Advisors and believe that I can make a significant difference in helping other athletes."
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "I am honored that Merril has joined our Board of Advisors. With his past career in the NFL and his experiences of injuries to players from limb injuries to concussions, he will bring a wealth of knowledge and help lead IntelliCell to assist other professional athletes. He is a perfect addition to our Board of Advisors that is lead by Dr. James Andrews, our Chairman of Cellular Orthopedic Sports Medicine. Also, we believe Merril's ESPN on-air experience and reach will help us get our message out to both professional and amateur athletes alike. We believe that IntelliCell's Stromal Vascular Fraction Cells injected locally into the site of injury will give hope to athletes for a nonsurgical method to treat their orthopedic concerns."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Merril Hoge
Merril Hoge is an NFL analyst for ESPN. These programs include NFL Live, NFL Matchup, NFL PrimeTime, SportsCenter and NFL Countdown!
An eight-year NFL veteran, Hoge spent 1987-93 with the Pittsburgh Steelers where he set the team record for most receptions by a running back, totaling 50 in 1988 and was one of only two Steelers to rush for more than 100 yards in back-to-back playoff games, the other being Franco Harris. He was Iron Man of the year 2 years in a row and was named to the All Madden Team in 1990. He concluded his career in 1995 with the Chicago Bears after suffering a series of concussions. At the time of his retirement, Hoge had played in 122 consecutive games, the longest streak in the NFL at that time.
Outside of his television work, Hoge is Chairman of the Board of the Highmark Caring Foundation, which is a center for grieving children, adolescents and their families who have lost loved ones. The foundation is particularly meaningful to Hoge, who lost his mother when he was just 21 years old.
Hoge, who battled Non-Hodgkins Lymphoma in 2003, received the Chairman's Advocacy Award from the Leukemia & Lymphoma Society in 2004 and 2008 for his outstanding participation in driving awareness for LLS and its mission. Hoge is also extremely active in concussion research and in the prevention and treatment of brain injuries. In the fall of 2009, Hoge testified at a congressional hearing on head injuries in football, and in January 2010, he was appointed to the NFL MTBI Committee, which initiates research and advises the NFL on the best practices for concussion prevention and management. He also sat on the Board of USA Football, where he feels he has his greatest impact on all the youth that play the game of football.
September 2010, Hoge released his first book, titled, "Find a Way: Three Words That Changed My Life". The book is about his life philosophy that has helped guide him to success and through many challenges.
Disclaimer: This press release contains anecdotal statements of regarding cell therapy treatment. Treatment results experienced by Mr. Hoge may not be indicative of results for other individuals in other situations. Mr. Hoge's results are included to help illustrate why he decided to join IntelliCell's Board of Advisors, and not as evidence of effectiveness.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
SOURCE IntelliCell BioSciences, Inc.